Unlock instant, AI-driven research and patent intelligence for your innovation.

Therapies based on control of regulatory t cell stability and function via a neuropilin-1:semaphorin axis

a technology of semaphorin and t cell, applied in the direction of fusion polypeptide, cell culture active agents, dna/rna fragmentation, etc., to achieve the effect of enhancing the survival of inflammatory sites and potentiating treg function

Inactive Publication Date: 2017-05-18
ST JUDE CHILDRENS RES HOSPITAL INC
View PDF2 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

This approach allows for therapeutic modulation of Treg activity, enhancing anti-tumor responses, treating autoimmune diseases, and improving vaccine efficacy by selectively targeting the Nrp1:semaphorin axis, thereby addressing the limitations of existing treatments for cancer, infections, and autoimmune conditions.

Problems solved by technology

However, they also represent a major barrier to effective anti-tumor immunity and sterilizing immunity to chronic viral infections.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Therapies based on control of regulatory t cell stability and function via a neuropilin-1:semaphorin axis
  • Therapies based on control of regulatory t cell stability and function via a neuropilin-1:semaphorin axis
  • Therapies based on control of regulatory t cell stability and function via a neuropilin-1:semaphorin axis

Examples

Experimental program
Comparison scheme
Effect test

example 1

Materials and Methods

[0188]Mice.

[0189]C57 / BL6 and dnTGFI3RII mice were purchased from the Jackson Laboratories. Foxp3YFP-iCre, Foxp3− and Foxp3DTR-gfp mice were obtained from A. Y. Rudensky (HHMI / Washington University; see Rubtsov et al., Immunity, 2008, 28:546-558; Fontenot et al., Nat Immunol., 2003, 4(4):330-336; Kim et al., Nat Immunol., 2007, 8(2):191-197). Il10− / − mice were obtained from T. Geiger (St. Jude Children's Research Hospital; see Selvaraj and Geiger, J Immunol., 2008, 180(5):2830-2838). Nrp1f / f mice were obtained from D. Cheresh (UCSD; see Acevedo et al., Blood, 2008, 111(5):2674-2680). Foxp3−× CD45.1 mice were bred from heterozygous crosses. Animal experiments were performed in American Association for the Accreditation of Laboratory Animal Care-accredited, specific-pathogen-free facilities in the St. Jude Animal Resource Center. Animal protocols were approved by the St Jude Animal Care and Use Committee.

[0190]Nrp1 and Semaphorin Antibodies.

[0191]Mouse Sema-3a, mou...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
stabilityaaaaaaaaaa
Login to View More

Abstract

The invention is directed to treatment of cancer, infections and various inflammatory and autoimmune conditions by affecting regulatory T cell stability and function via a Neuropilin-1:Semaphorin axis.

Description

CROSS REFERENCE TO RELATED APPLICATIONS[0001]This application is a divisional of 371 U.S. application Ser. No. 14 / 434,129, filed Apr. 8, 2015, which claims benefit to U.S. National Phase of International Patent Application No. PCT / US2013 / 063934, filed Oct. 8, 2013, which claims the benefit of U.S. Provisional Patent Application No. 61 / 784,607, filed Mar. 14, 2013, U.S. Provisional Application No. 61 / 712,679, filed Oct. 11, 2012, and U.S. Provisional Application No. 61 / 711,193, filed Oct. 8, 2012. The International Application was published on Apr. 17, 2014 as International Publication No. WO 2014 / 058915 A2 under PCT Article 21(2). The entire contents of all of these applications are hereby incorporated by reference, in their entiry, for all purposes.STATEMENT AS TO FEDERALLY SPONSORED RESEARCH[0002]The United States Government has certain rights to this invention by virtue of funding reserved from Grant Nos. AI091977, AI039480 and AI098383 from the National Institutes of Health and ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): C07K16/28A61K45/06A61K39/395A61K39/00
CPCC07K16/2863A61K39/0011A61K45/06C07K2317/32C07K2317/76A61K2039/5158A61K2039/505A61K39/39541A61K39/4621A61K39/4644A61K39/46433A61K39/4611A61K38/1709C07K16/2803A61K31/713C12N5/0637A01K2217/075C07K2317/73C07K2319/30C07K2319/32A01K2227/105A01K2267/0387C12N2501/165C12N15/1138C12N2310/14A61P1/04A61P1/14A61P11/06A61P17/00A61P17/02A61P17/06A61P19/02A61P21/04A61P25/00A61P29/00A61P31/00A61P31/04A61P35/00A61P35/02A61P37/02A61P37/06A61P37/08A61P43/00A61P5/14A61P9/10A61P3/10A61K2239/50A61K2239/57A61K2239/38A61K2239/52A61K2239/31
Inventor VIGNALI, DARIO A. A.WOO, SENG-RYONGDELGOFFE, GREG M.
Owner ST JUDE CHILDRENS RES HOSPITAL INC